What do the latest data tell us about the European drug market? What are the new trends in drug use among European adults and school students? What are the harms associated with drug use and what is being done to counter them? These and other questions will be explored by the EU drugs agency (EMCDDA) on 6 June in its annual overview of the European drug situation.
The European Drug Report 2017: Trends and Developments, provides a comprehensive analysis of the latest tendencies across the 28 EU Member States, Turkey and Norway. In print and pdf in 24 languages, the report examines: drug supply and the market; drug use prevalence and trends; and drug-related harms and responses to them. Accompanying the report will be the 2017 Statistical Bulletin, containing the European dataset underpinning the analysis.
The report will be complemented for the first time by 30 Country Drug Reports, presenting summaries of national drug phenomena (EU 28, Turkey and Norway). Developed by the EMCDDA, in cooperation with the Reitox national focal points, these graphic-rich reports cover: drug use and public health problems; drug policy and responses and drug supply.
Date: 6 June 2017
Time: 12:45 Central European Time/CET (11:45 Lisbon)
Venue: European Commission, press room, Berlaymont, Brussels.
Press conference: In the presence of Dimitris Avramopoulos, European Commissioner responsible for Migration, Home Affairs and Citizenship; Laura d’Arrigo, Chair of the EMCDDA Management Board and Alexis Goosdeel, EMCDDA Director.
Contact: European Commission spokespersons’ service — Tove Ernst (32) 2 298 67 64; Markus Lammert (32) 2 298 04 23. See Media support box for EMCDDA press office contacts.
Interviews: EMCDDA representatives will be available on the day of the launch to answer journalists’ questions. Across Europe, staff at the Reitox national focal points will answer country-specific queries (interview details available via the link below).
Find out more: www.emcdda.europa.eu/edr2017